Maya Ameyar
Impact in
-
- NF-κB Signaling Pathways
-
- Immune Response and Inflammation
- interferon and immune responses
Papers in
-
- Cell death mechanisms and regulation 5
- Protein Kinase Regulation and GTPase Signaling 2
- Ubiquitin and proteasome pathways 1
-
- NF-κB Signaling Pathways 4
- Co-authors
- M. Wisniewska (1 shared paper)Jonathan B Weitzman (1 shared paper)Salem Chouaı̈b (7 shared papers)Anne‐Cecile Hellin (1 shared paper)Zhenzi Cai (5 shared papers)M. P. Merville (1 shared paper)Mohamed Bentires‐Alj (2 shared papers)Vincent Bours (2 shared papers)
In The Last Decade
Maya Ameyar
10 papers receiving 477 citations
Peers
Comparison fields: 5 of 85
- Cancer Research 127
- Immunology 99
- Oncology 108
- Molecular Biology 277
- Toxicology 11
Countries citing papers authored by Maya Ameyar
This map shows the geographic impact of Maya Ameyar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maya Ameyar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maya Ameyar more than expected).
Fields of papers citing papers by Maya Ameyar
This network shows the impact of papers produced by Maya Ameyar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maya Ameyar. The network helps show where Maya Ameyar may publish in the future.
Co-authors
The 25 scholars most cited alongside Maya Ameyar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 260 | |
| 2 | Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. | 1999 | 83 |
| 3 | 1999 | 32 | |
| 4 | 2007 | 27 | |
| 5 | 2000 | 22 | |
| 6 | 1998 | 20 | |
| 7 | 2001 | 15 | |
| 8 | 2000 | 14 | |
| 9 | Methyltransferase inhibitor S-adenosyl-L-homocysteine sensitizes human breast carcinoma MCF7 cells and related TNF-resistant derivatives to TNF-mediated cytotoxicity via the ceramide-independent pathway. | 1999 | 10 |
| 10 | 2001 | 4 |
About Maya Ameyar
Maya Ameyar is a scholar working on Molecular Biology, Cancer Research, Immunology, Oncology and Biotechnology, having authored 10 papers that have together received 487 indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (5 papers), NF-κB Signaling Pathways (4 papers), Cancer-related Molecular Pathways (2 papers), Cancer Research and Treatments (2 papers), Immune Cell Function and Interaction (2 papers), Protein Kinase Regulation and GTPase Signaling (2 papers), Ubiquitin and proteasome pathways (1 paper) and Bioactive Compounds and Antitumor Agents (1 paper). The work is most often cited by research in Cancer Research (127 citations), Immunology (99 citations), Oncology (108 citations), Molecular Biology (277 citations) and Toxicology (11 citations). Maya Ameyar has collaborated with scholars based in France, Belgium and Germany. Frequent co-authors include M. Wisniewska, Jonathan B Weitzman, Salem Chouaı̈b, Anne‐Cecile Hellin, Zhenzi Cai, M. P. Merville, Mohamed Bentires‐Alj, Vincent Bours, В. А. Шатров and Rodica Stancou. Their work appears in journals such as International Journal of Cancer, Oncogene, European Journal of Immunology, The Journal of Immunology and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.